Background Transcutaneous immunization (TCI) approaches utilize skin associated lymphatic tissues to elicit specific immune responses. In this context, the imidazoquinoline derivative imiquimod formulated in Aldara applied onto intact skin together with a cytotoxic T lymphocyte (CTL) epitope induces potent CTL responses. However, the feasibility and efficacy of the commercial imiquimod formulation Aldara is limited by its physicochemical properties as well as its immunogenicity. Methodology/Principal Findings To overcome these obstacles, we developed an imiquimod-containing emulsion gel (IMI-Gel) and characterized it in comparison to Aldara for rheological properties and in vitro mouse skin permeation in a Franz diffusion cell system. Imiquimod was readily released from Aldara, while IMI-Gel showed markedly decreased drug release. Nevertheless, comparing vaccination potency of Aldara or IMI-Gel-based TCI in C57BL/6 mice against the model cytotoxic T-lymphocyte epitope SIINFEKL, we found that IMI-Gel was equally effective in terms of the frequency of peptide-specific T-cells and in vivo cytolytic activity. Importantly, transcutaneous delivery of IMI-Gel for vaccination was clearly superior to the subcutaneous or oral route of administration. Finally, IMI-Gel based TCI was at least equally effective compared to Aldara-based TCI in rejection of established SIINFEKL-expressing E.G7 tumors in a therapeutic setup indicated by enhanced tumor rejection and survival. Conclusion/Significance In summary, we developed a novel imiquimod formulation with feasible pharmaceutical properties and immunological efficacy that fosters the rational design of a next generation transcutaneous vaccination platform suitable for the treatment of cancer or persistent virus infections.
References
[1]
Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA (2010) Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release 148: 266–282 doi:10.1016/j.jconrel.2010.09.018.
[2]
Mikszta JA, Laurent PE (2008) Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook. Exp Rev Vaccines 7: 1329–1339. doi: 10.1586/14760584.7.9.1329
[3]
Kermode M (2004) Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot Int 19: 95–103. doi: 10.1093/heapro/dah110
[4]
Pisani E, Miller MA (1999) The cost of unsafe injections. Bulletin of the World Health Organization 77: 808.
[5]
Stein P, Rechtsteiner G, Warger T, Bopp T, Fuhr T, et al. (2011) UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin. J Invest Dermatol 131: 211–219 doi:10.1038/jid.2010.254.
[6]
Glenn GM, Rao M, Matyas GR, Alving CR (1998) Skin immunization made possible by cholera toxin. Nature 391: 851 doi:10.1038/36014.
[7]
van den Berg JH, Oosterhuis K, Hennink WE, Storm G, van der Aa LJ, et al. (2010) Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. Journal of Controlled Release 141: 234–240 doi:10.1016/j.jconrel.2009.09.005.
[8]
Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP (2005) Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 174: 2476–2480. doi: 10.4049/jimmunol.174.5.2476
[9]
Warger T, Rechtsteiner G, Schmid B, Osterloh P, Schild H, et al. (2007) Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clinic Rev Allerg Immunol 32: 57–66. doi: 10.1007/bf02686082
[10]
Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, et al. (2008) Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J Immunol 180: 1991–1998. doi: 10.4049/jimmunol.180.3.1991
[11]
Stein P, Weber M, Prüfer S, Schmid B, Schmitt E, et al. (2011) Regulatory T Cells and IL-10 Independently Counterregulate Cytotoxic T Lymphocyte Responses Induced by Transcutaneous Immunization. PLoS ONE 6: e27911. doi: 10.1371/journal.pone.0027911
[12]
Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, et al. (1998) Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 134: 25–30. doi: 10.1001/archderm.134.1.25
[13]
Navi D, Huntley A (2004) Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J 10: 4.
[14]
Adams S, O’Neill DW, Nonaka D, Hardin E, Chiriboga L, et al. (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181: 776–784. doi: 10.4049/jimmunol.181.1.776
[15]
Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, et al. (2009) Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69: 917–927 doi:10.1002/pros.20941.
[16]
Gogoll K, Stein P, Wei H, Schild H, Radsak M, et al. (2012) Comparative transcutaneous immunization with imiquimod-containing ointments and potential of in vitro methods to predict effects. Biopharm Drug Dispos 33: 218–228 doi:10.1002/bdd.1787.
[17]
Walter A, Sch？fer M, Cecconi V, Matter C, Urosevic-Maiwald M, et al. (2013) Aldara activates TLR7-independent immune defence. Nat Comms 4: 1560 doi:10.1038/ncomms2566.
[18]
Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone AM, et al. (1989) Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 169: 1169–1178 Available: http://eutils.ncbi.nlm.nih.gov/entrez/eu？tils/elink.fcgi?dbfrom=pubmed&id=2522497？&retmode=ref&cmd=prlinks.
[19]
Hilleman MR (2000) Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 18: 1436–1447. doi: 10.1016/s0264-410x(99)00434-x
[20]
Sharma P, Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11: 805–812 doi:10.1038/nrc3153.
[21]
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med 363: 411–422 doi:10.1056/NEJMoa1001294.
[22]
Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, et al.. (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. doi:10.1038/nm.2883.
[23]
Matsuo K, Ishii Y, Quan Y-S, Kamiyama F, Mukai Y, et al. (2011) Characterization of Transcutaneous Protein Delivery by a Hydrogel Patch in Animal, Human, and Tissue-Engineered Skin Models. Biol Pharm Bull 34: 586–589 doi:10.1248/bpb.34.586.
[24]
Matsuo K, Hirobe S, Okada N, Nakagawa S (2013) Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery. Vaccine 31: 2403–2415 doi:10.1016/j.vaccine.2013.03.022.
[25]
Knorr F, Lademann J, Patzelt A, Sterry W, Blume-Peytavi U, et al. (2009) Follicular transport route – Research progress and future perspectives. European Journal of Pharmaceutics and Biopharmaceutics 71: 173–180 doi:10.1016/j.ejpb.2008.11.001.
[26]
Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, et al. (2006) Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108: 544–550 doi:––10.1182/blood-2005–10–4015.
[27]
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, et al. (1998) Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells. Nat Med 4: 328–332 doi:–10.1038/nm0398–328.
[28]
Paula DD, Martins CA, Bentley MVLB (2008) Development and validation of HPLC method for imiquimod determination in skin penetration studies. Biomed Chromatogr 22: 1416–1423 doi:10.1002/bmc.1075.
